LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Inicio・Lista de Acciones・BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

Cerrado

SectorSanidad

53.74 0.84

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

53.03

Máximo

53.97

Métricas clave
By Trading Economics
Ingresos	-457M -31M
Ventas	-49M 776M
P/B Media del Sector	19.814 77.671
BPA	1.44
Margen de beneficios	-3.961
Empleados	3,040
EBITDA	-324M -5.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+61.13% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-221M 10B
Apertura anterior	52.9
Cierre anterior	53.74

Noticias sobre sentimiento de mercado

By Acuity

61%

39%

166 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

59.405 / 62.19 Soporte y Resistencia

BioMarin Pharmaceutical Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 dic 2025, 22:13 UTC

Ganancias

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dic 2025, 21:40 UTC

Ganancias

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dic 2025, 18:51 UTC

Adquisiciones, fusiones, absorciones

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dic 2025, 16:57 UTC

Principales Movimientos del Mercado

Clear Secure Rises on Medicare Identity Verification Contract

9 dic 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dic 2025, 23:46 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings Stake in Lenovo Now at 32.34%

9 dic 2025, 23:45 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dic 2025, 23:44 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dic 2025, 23:43 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dic 2025, 23:43 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dic 2025, 23:35 UTC

Charlas de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dic 2025, 22:42 UTC

Ganancias

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dic 2025, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

9 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 dic 2025, 21:48 UTC

Charlas de Mercado

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dic 2025, 20:28 UTC

Charlas de Mercado

Oil Futures Decline for Second Straight Session -- Market Talk

9 dic 2025, 20:27 UTC

Adquisiciones, fusiones, absorciones

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dic 2025, 20:27 UTC

Adquisiciones, fusiones, absorciones

Teck Reports Voting Results From Special Meeting of Hldrs

9 dic 2025, 20:26 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dic 2025, 20:21 UTC

Charlas de Mercado

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dic 2025, 19:52 UTC

Ganancias

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dic 2025, 19:17 UTC

Ganancias

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 dic 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

9 dic 2025, 17:11 UTC

Ganancias

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Comparación entre iguales

Cambio de precio

BioMarin Pharmaceutical Inc previsión

Precio Objetivo

By TipRanks

61.13% repunte

Estimación a 12 Meses

Media 85.88 USD 61.13%

Máximo 120 USD

Mínimo 55 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioMarin Pharmaceutical Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

Comprar

Mantener

Vender

De acuerdo con 19 analistas que ofrecen calificaciones bursátiles a para BioMarin Pharmaceutical Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

59.405 / 62.19Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentimiento

By Acuity

166 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.